Education
Level 1: Physique EssentialsApplied Hypertrophy Optimization (AHO)Female Physique Module
Training Programs
X-Frame ProgramHourglass Program
Coaching
Apply for Coaching
Community
J3U Hub (Free)Applied LabAffiliate Program
More
BlogMerch
Student portal Join Now
J3 University · PEDs

Peptides for Fat Loss: What Works, What Supports, and What I Skip

Short answer

The peptides for fat loss with the strongest support are growth hormone and retatrutide, and they work differently. Growth hormone shifts resting fuel use toward fat and helps conserve body protein. Retatrutide may lower intake and increase energy expenditure. Most of the rest support recovery or health rather than fat loss.

Education, not medical advice. Make medication decisions with your doctor.

What do peptides for fat loss actually do?

For physique athletes, successful fat loss means more than a lower scale weight. The goal is to reduce body fat, preserve or build muscle, and maintain the training performance that supports both. Judge each compound against all three.

These compounds work differently. Some affect energy balance or fuel use: retatrutide's glucagon receptor activity may increase energy expenditure, while growth hormone shifts resting fuel use toward fat. Others may influence appetite, diet tolerance, or joint symptoms without directly increasing fat loss. Some lack evidence of meaningful benefit.

This article is for enhanced physique athletes working with a provider. Enhancement changes your physiology, but diet, training, and the psychology of prep still matter.

Throughout, I distinguish three types of evidence, and each recommendation identifies which type supports it:

  • Human outcomes: Results measured in people in clinical trials.
  • Proposed mechanisms: How a compound might work, often based on cell or animal research. These do not establish human benefits.
  • Coaching and personal experience: Observations from my own use and the athletes I coach, which cannot establish cause and effect or predict everyone's response.

Is HGH the best peptide for fat loss?

For physique athletes, a successful diet means losing fat, retaining muscle, and maintaining productive training. GH is one of the compounds I value most because its effects are relevant to all three, although the evidence is stronger for some benefits than others.

First, it changes how you use fuel. GH mobilizes stored fat and increases its availability for energy. During fasting and other catabolic conditions, greater fat oxidation reduces reliance on glucose and protein, helping conserve glycogen and body protein.1,2 This supports its role in nutrient partitioning, but releasing stored fat still needs to translate into net fat loss through a calorie deficit.

Second, it helps conserve body protein. By shifting fuel use toward fat, GH reduces reliance on amino acids for energy. Human fasting research supports this protein sparing effect, making it relevant to the goal of retaining muscle during a calorie deficit.1,2 GH also stimulates IGF-1, which participates in muscle growth and tissue adaptation.1 Together, these effects explain why I view GH as more than a fat loss tool, although they do not establish how much additional muscle it preserves during contest prep.

Third, it supports connective tissue turnover. A human study found increased collagen synthesis in tendon and the connective tissue around muscle, without increased synthesis of the muscle's contractile proteins.3 This is relevant to the structures we load during training, although it does not establish faster injury repair or protection from injury during prep. Maintaining productive training is essential to retaining muscle, which is why this effect matters to my reasoning.

My own experience is what makes GH particularly valuable to me, but that is separate from the research. In 2023, I moved from 212 to Open and increased my GH use well beyond physiological levels. Over the eight weeks between my last 212 show and first Open show, my weight climbed each week while my conditioning appeared unchanged. I went from being stage lean at 214 before cutting weight for 212 to competing at 223 in Open.

What stood out was bringing a heavier, fuller physique to the stage without appearing softer. Since then, I have found it easier to maintain a lean baseline, shorten preps, and retain fullness. I cannot attribute that entire change to GH or call all the added weight muscle, but those observations explain why I value it beyond fat loss alone.

Water retention is the main complication when assessing the physique. GH can increase extracellular fluid, so added weight or fullness may reflect water rather than muscle, and conditioning can become harder to judge.4,5 Around six weeks out, I reassess whether fluid retention is obscuring the picture, with any changes coordinated with the athlete's provider. That is my assessment checkpoint, not a universal withdrawal timeline.

Do GH secretagogues like ipamorelin, CJC-1295, and tesamorelin work for fat loss?

This is where I started. In 2015, I ran ipamorelin with what is commonly called CJC-1295 without DAC, or more accurately modified GRF 1-29. For many people, the appeal is access: they encounter secretagogues through peptide clinics, prescribing providers, or research peptide websites when pharmaceutical GH feels harder to obtain. Those sources are not equivalent, but accessibility helps explain why people go down this path.

The simplest distinction is that secretagogues ask your body to release GH; exogenous GH supplies the hormone directly.

Tesamorelin and modified GRF 1-29 stimulate the GHRH receptor, delivering a signal that tells the pituitary to release GH. Ipamorelin delivers a different signal through the ghrelin receptor. Think of these as two inputs to the same control room: combining modified GRF with ipamorelin is intended to produce a greater GH response than either signal alone. Early research also identified ipamorelin's relative selectivity for GH release over ACTH and cortisol release.6

But a bigger GH pulse is a hormonal outcome, not proof of fat loss. Human body composition evidence for the ipamorelin and modified GRF combination remains limited.

Tesamorelin has stronger direct evidence. Human research demonstrates effects on GH pulsatility and IGF-1,7 and its approved clinical use is reducing visceral fat accumulation in people with HIV. That is meaningful, but visceral fat around the organs is different from the subcutaneous fat a bodybuilder needs to lose for stage condition. Those results cannot simply be transferred to contest prep.

In my own use, the combination also introduced practical constraints. I organized injections around a fasted window, which was restrictive while eating multiple meals a day. That was my approach to using ipamorelin and modified GRF. It is not a universal requirement for secretagogues. Tesamorelin's prescribing information does not require fasting or bedtime administration.

Regardless of the compound, mobilizing fat is only part of the process. Releasing fatty acids makes stored energy available; it does not guarantee net fat loss. You still need an energy deficit, and you do not have to perform fasted cardio immediately after an injection for those fatty acids to be used.

The other distinction is how much stimulation your own GH axis can deliver. Secretagogues depend on a functioning pituitary and remain subject to physiological feedback. Exogenous GH bypasses the need to stimulate that release. This is not an absolute ceiling, since tesamorelin can raise IGF-1 above normal, but it helps explain why the approaches are not interchangeable.

Across the clients I have coached, secretagogues have not come close to the physique changes I have observed with exogenous GH, particularly with supraphysiological exposure and the IGF-1 elevations that can accompany it. That is my coaching experience, not a head to head clinical trial, and higher hormone levels alone do not establish a better outcome.

So who are secretagogues for? For someone whose access is limited and who is pursuing treatment through a provider, they may be an option depending on the compound and clinical indication. Tesamorelin has a demonstrated clinical application; the ipamorelin and modified GRF combination has much less outcome evidence.

For the bodybuilder pursuing extreme physique development, GH remains the more powerful tool in my experience. Access may make secretagogues appealing, but I would not present them as delivering an equivalent result.

Is retatrutide better than tirzepatide for fat loss?

On raw effectiveness, yes, and the margin is meaningful. Retatrutide is an investigational once weekly triple receptor agonist, hitting GLP-1, GIP, and glucagon receptors at the same time. In Phase 3 trials it averaged up to 28.3% of body weight lost over 80 weeks, with nearly half of participants losing 30% or more.8

The glucagon arm is what separates it. Semaglutide and tirzepatide work almost entirely by getting you to eat less. Glucagon receptor activation directly stimulates fat oxidation in the liver, thermogenesis, and lipolysis, pushing energy expenditure up rather than only pulling intake down.9 That is a direct answer to adaptive thermogenesis, the drop in resting metabolic rate that shows up in any prolonged diet.

The second reason I favor it for physique goals is how that receptor balance plays out in practice. Because retatrutide is not relying solely on heavy GLP-1 receptor saturation to drive results, many athletes find they can run effective doses with milder gastric slowing and less total appetite wipeout than with semaglutide.10 In a prep, still being able to eat your food, and hit your daily protein targets to hold onto muscle, is not a small thing.

The honest caveats are side effects and supply. On the clinical side, that same glucagon driven metabolic push can cause a noticeable bump in resting heart rate, which is worth watching if you are already running other compounds.8,10 More importantly, it is not FDA approved, with a filing planned for early 2027, so there is real risk in sourcing it.11 It cannot be legally prescribed or compounded outside a registered trial, which means anything sold online as a research peptide is unregulated. Independent testing on those vials keeps finding product that is under dosed, over dosed, or contaminated.12 Tirzepatide gets you most of the effect with a verified safety record, and for a lot of people that is the better trade.

SemaglutideTirzepatideRetatrutide
ReceptorsGLP-1GLP-1 and GIPGLP-1, GIP and glucagon
Main driverAppetite suppression, delayed gastric emptyingStronger satiety, better adipose lipid handlingAppetite suppression plus raised energy expenditure
Trial weight lossRoughly 15% at 68 weeks13Roughly 21% at 72 weeks14Up to 28.3% at 80 weeks
Liver fat reductionModerateHighVery high15
StatusApprovedApprovedInvestigational

How do I use retatrutide in prep and after a show?

Everything in this section is my coaching experience, not trial data. The trials tell you what the compound does to untrained people with a lot of fat to lose. They tell you nothing about running it through a contest prep, so take the following as how I use it rather than as an established protocol.

Retatrutide shines in prep and I used it in my last one. The thing a bodybuilder has to keep in mind is that very low dosing goes very far. We are not the trial population. Those participants were not training and were carrying far more fat than we are.

It also pairs well with growth hormone, because the insulin resistance growth hormone creates is offset by the reta.

Timing out of it is the part people get wrong. It has a long half life and it delays gastric emptying, which will wreck a peak week carb load.16–19 I taper it down around 3 weeks out and then pull it completely so gut motility is fully back to normal. Once the fat loss work is done, get it out if you do not need it. You can run a little flatter on it.

In the offseason I think it mostly has no place, and I say that from trying it. Insomnia and an elevated heart rate are both on the side effect list,8,10 and the raised heart rate alone was waking me up at night. My recovery was terrible even at a very low dose, and because of the energy expenditure I was having to eat more food just to keep up. It turned into a vicious cycle. If someone genuinely struggles with hunger in an offseason, I would reach for tirzepatide instead, where you are not force feeding to offset the expenditure.

Where it has surprised me most is after a show. Reintroducing it post show has helped my athletes stay in control of their eating during the window where that usually falls apart. It appears to work on the dopamine side, taking some of the reward out of very palatable food. I have a client who historically struggled with eating off plan after a show and would come up 25 lbs from stage weight within the first couple of weeks. Bringing it in 2 weeks after the show, they sat at just 4 lbs up from stage weight, in a healthy spot, and I could control intake and walk them into the offseason instead of overshooting it.

That said, it is not something you want anyone leaning on. The goal is an athlete who learns how to eat. The compound buys you a window to teach that, not a replacement for it.

Which peptides do not belong on a fat loss list?

The HGH fragment is the clearest example, and it gets sold hard under two names. The fragment 176 to 191 is the tail end of the growth hormone molecule, the stretch that handles fat metabolism on its own. AOD-9604 is essentially a stabilized version of that same fragment, with one amino acid swapped at the front so it survives longer. People talk about them as if they were different compounds. In practice they are nearly the same molecule, and suppliers use the names interchangeably.

The pitch for both is lipolysis without the rest of growth hormone. That pitch is exactly the problem, because the rest of growth hormone is most of why it works for a physique athlete. Strip the molecule down and you lose the IGF-1 driven muscle sparing, the collagen synthesis that keeps you training, and the sleep quality. A weaker version of one benefit and none of the others.

The evidence is thin on top of that. AOD-9604 did reach human obesity trials and failed its weight loss endpoints, which is why it never became a drug.20 The native fragment has almost no published human efficacy data at all.21 Growth hormone is still the king of this list precisely because it does the whole job instead of one piece of it.

The rest of this group fails for its own reasons, worth knowing because vendors still move all of it as fat loss product.

In this article I am leaving out small molecules, as currently many people are referring to these in the bucket of peptides when they are not actual peptides. An example is SLU PP332 and all those like it.

CompoundThe pitchWhy I skip it
AOD-9604 and the fragment 176 to 191Fat loss without raising IGF-1 or blood sugarHuman trials failed to beat placebo,20 and removing IGF-1 removes the muscle sparing and collagen support you wanted
CJC-1295 with DACLonger action, fewer injectionsBinds to albumin and stays active for days,22 giving a flat continuous bleed instead of pulses. Desensitizes the pituitary, holds more water, partitions worse
SermorelinAn older GHRH analogHalf life of roughly 10 to 20 minutes and structurally unstable,23 so enzymes break it down before a real pulse builds
GHRP-2 and GHRP-6Strong acute GH spikesThey deliver the spike and a brutal hunger response with it, plus cortisol and prolactin.24,25 Driving hunger up in a deficit is the wrong trade
HexarelinThe most potent of the ghrelin receptor groupDesensitizes pituitary receptors within weeks,26 so the benefit fades while you are still paying for it

Where do BPC-157, TB-500, SS-31 and MOTS-c fit?

These come up in every fat loss conversation, so they are worth placing properly. None of them is a fat loss compound. They support the athlete doing the fat loss, which is a different job and still a valuable one. An athlete who expects a recovery peptide to move body fat concludes the whole category is useless, when the real error was the expectation.

Read this whole section as proposed mechanism rather than demonstrated outcome. Almost everything here rests on cell and animal work plus user reports. That is a different tier of evidence from the growth hormone and retatrutide sections above, and I am not going to pretend otherwise.

One connection runs back to the growth hormone section. Tendons heal slowly partly because they have poor blood supply and few hormone receptors compared with muscle. Tendon cell studies show BPC-157 raises growth hormone receptor expression on those cells while also driving new capillary growth.27,28 More receptors to catch the signal, better delivery to catch it with. Worth understanding if you are already running growth hormone in a prep, with the caveat that this is cell and animal work.

Be straight with yourself about the evidence on these two. Neither BPC-157 nor TB-500 has long term human safety data. That is the honest status, and it is why I treat them as short term tools for a specific problem rather than something you run continuously.

  • BPC-157: localized tissue recovery and tendon repair, plus gut lining support. No fat loss mechanism at all. I reach for it through harder stints of training or when an acute injury shows up, and it earns its place deep in a prep when low body fat and reduced water leave joints and tendons exposed.
  • TB-500: a thymosin fragment that works systemically rather than locally, mobilizing repair cells to sites of micro trauma.29 That same property is the reason to be careful with it. It promotes cell migration and angiogenesis, and elevated thymosin beta 4 has been observed in certain rapidly proliferating tissues.30 Use it cautiously, for short stretches, and only when there is an actual injury to treat.
  • SS-31: binds cardiolipin in the mitochondrial membrane and stabilizes the electron transport chain, cutting oxidative stress at its source.31 The heart and kidneys are the densest mitochondrial tissue in the body, which is why it interests enhanced athletes putting those organs under real strain. Approved only for a rare genetic condition and unproven in healthy lifters. A health consideration, not a physique one.
  • MOTS-c: an exercise mimetic, encoded in mitochondrial DNA, that activates AMPK and mimics some of the signaling of exercise and fasting.32,33 From my own use I have not seen it contribute much to actual energy expenditure. What I have noticed is cognitive function and an improved metabolic profile. I suspect it shines more in an offseason, on high food and growth hormone, keeping metabolic flexibility intact. Human data is early.

Who should not use any of this?

Drug tested competitors, straightforwardly. None of this applies to you. Several of these compounds are specifically prohibited in tested sport,34 including the recovery and health ones people assume are harmless.

Anyone with an active or recent malignancy should not be touching these compounds. There are real concerns there across this entire class.

More broadly, this is exactly why anyone considering any of it needs a provider who can assess whether it is appropriate for them specifically. I can tell you how these work and what I have watched happen in my athletes. I cannot tell you what belongs in your body. That decision gets made with someone who can run your labs and look at your history.

Frequently asked

Do peptides burn fat on their own?

No. A calorie deficit drives fat loss and nothing here replaces it. What these compounds change is which fuel your body prefers, how much muscle you hold onto, and how manageable the diet feels while you run it.

Is retatrutide good for an offseason?

In my experience it mostly is not. The raised heart rate and insomnia hurt my recovery even at a very low dose, and the extra energy expenditure meant eating more food to keep up. If hunger is genuinely the problem in an offseason, tirzepatide is the more sensible choice.

How long before a show should you stop a GLP-1?

Far enough out that gut motility is fully normal before you carb load. The delayed gastric emptying will interfere with peak week. I taper around 3 weeks out and then remove it completely.

Is AOD-9604 worth using for fat loss?

I skip it. It is a fragment of the growth hormone molecule with the IGF-1 driven effects removed, which means you lose the muscle preservation and connective tissue support that make growth hormone worth running in a deficit.

Is the HGH fragment the same thing as AOD-9604?

Close to it. AOD-9604 is a stabilized version of the fragment with one amino acid swapped at the front, and suppliers often use the names interchangeably. Neither raises IGF-1, which is why I would run growth hormone instead.

Can you run growth hormone and retatrutide together?

They pair well. Growth hormone creates a mild insulin resistance as part of how it shifts fuel selection, and the retatrutide offsets it. That combination is most relevant in a prep rather than an offseason.

References

  1. Møller N, Jørgensen JOL. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152-177. doi:10.1210/er.2008-0027
  2. Møller N, Gjedsted J, Gormsen L, Fuglsang J, Djurhuus C. Effects of growth hormone on lipid metabolism in humans. Growth Horm IGF Res. 2003;13(suppl A):S18-S21. doi:10.1016/s1096-6374(03)00048-0
  3. Doessing S, Heinemeier KM, Holm L, et al. Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. J Physiol. 2010;588(pt 2):341-351. doi:10.1113/jphysiol.2009.179325
  4. Møller J, Jørgensen JO, Møller N, Hansen KW, Pedersen EB, Christiansen JS. Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man. J Clin Endocrinol Metab. 1991;72(4):768-772. doi:10.1210/jcem-72-4-768
  5. Johannsson G, Sverrisdóttir YB, Ellegård L, Lundberg PA, Herlitz H. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J Clin Endocrinol Metab. 2002;87(4):1743-1749. doi:10.1210/jcem.87.4.8394
  6. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
  7. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. doi:10.1210/jc.2010-1587
  8. Jastreboff AM, Ryan DH, Bays HE, et al; TRIUMPH-1 Investigators. Once-weekly retatrutide in adults with obesity or overweight: the TRIUMPH-1 phase 3 trial. N Engl J Med. 2026;394(15):1412-1425.
  9. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
  10. Jastreboff AM, Kaplan LM, Frías JP, et al; Retatrutide Phase 2 Obesity Trial Investigators. Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
  11. Lilly's phase 3 TRIUMPH-1 trial of retatrutide met all primary and key secondary endpoints in adults with obesity or overweight. News release. Eli Lilly and Company. 2026. Accessed November 14, 2026. lilly.com
  12. FDA's concerns with unapproved GLP-1 drugs used for weight loss. US Food and Drug Administration. Updated December 18, 2024. Accessed November 14, 2026. fda.gov
  13. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
  14. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
  15. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2
  16. Halawi H, Khemani D, Eckert D, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2(12):890-899. doi:10.1016/S2468-1253(17)30285-6
  17. Dahl K, Brooks A, Almazedi F, Hoff ST, Boschini C, Baekdal TA. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23(7):1594-1603. doi:10.1111/dom.14373
  18. Wegovy (semaglutide) [prescribing information]. Novo Nordisk Inc; 2026. Accessed November 14, 2026. fda.gov
  19. Zepbound (tirzepatide) [prescribing information]. Eli Lilly and Company; 2024. Accessed November 14, 2026. fda.gov
  20. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15. doi:10.4021/jem157w
  21. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. doi:10.1159/000053183
  22. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
  23. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1989;83(5):1533-1540. doi:10.1172/JCI114049
  24. Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-614. doi:10.1210/jc.2004-1719
  25. Arvat E, di Vito L, Maccagno B, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-891. doi:10.1016/s0196-9781(97)00016-8
  26. Rahim A, O'Neill PA, Shalet SM. The growth hormone response to hexarelin undergoes partial desensitization during long-term administration in normal human subjects. Clin Endocrinol (Oxf). 1998;49(1):65-72. doi:10.1046/j.1365-2265.1998.00507.x
  27. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066
  28. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y
  29. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793
  30. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003;95(22):1674-1680. doi:10.1093/jnci/djg100
  31. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050. doi:10.1111/bph.12461
  32. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009
  33. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. doi:10.1038/s41467-020-20790-0
  34. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. World Anti-Doping Agency; 2026. Accessed November 14, 2026. wada-ama.org

Learn to read your own lab work

If you are running any of this, the labs are the part that actually keeps you safe, and most athletes have never been taught to read them. My free course inside the J3U Hub covers managing your health alongside PEDs and how to read your PED lab work.

Get the free course
John Jewett, IFBB Pro and founder of J3 University

About the author

John Jewett is an IFBB Professional bodybuilder and physique coach, and the founder of J3 University. He has spent his career competing at the professional level while coaching competitors and everyday lifters through the same training, nutrition, and recovery principles he uses himself.

J3 University exists to make that process teachable. Every course is built on the reasoning behind the method, not just the method, so you can make better decisions about your own physique long after the program ends.